Cite
HARVARD Citation
Le Calvez, B. et al. (2020). RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. EJHaem. 1 (1), pp. 318-322. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Le Calvez, B. et al. (2020). RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. EJHaem. 1 (1), pp. 318-322. [Online].